American Outdoor Brands announced a new $10 million stock repurchase program starting October 1, 2026, through September 30, 2027, following a prior program that repurchased about $1.9 million worth of shares. The company’s board expressed confidence in its strategy and a strong, debt-free balance sheet that supports innovation, growth, acquisitions, and shareholder returns. The repurchase will be executed flexibly based on market conditions and management discretion, aiming to enhance long-term shareholder value. This move signals the company's commitment to balancing growth investments with returning capital to investors.
American Outdoor Brands announced a $10 million share repurchase program starting October 1, 2026. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 02, 2026 01:51 WIB: out of 112 priced US stocks, 62 rose and 49 fell. Notable movers include JMIA at USD 6.96 (+4.66%), SFIX at USD 2.67 (+4.10%) with balanced buy/sell activity, and UA at USD 4.51 (+3.68%).
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
